Filing Flows › Bolt Biotherapeutics (BOLT) › Q2 2026
Bolt Biotherapeutics (BOLT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Bolt Biotherapeutics (BOLT) reported revenue of $5K for the second quarter 2026 (Q2 2026), -100% from a year earlier and -81% from the quarter before.
Bolt Biotherapeutics, Q2 2026: revenue $5K (-100% year over year), net loss $7.7M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5K | -81% | -100% |
| Operating profit | −$8.4M | — | — |
| Net earnings | −$7.7M | — | — |
| Operating cash flow | −$6.5M | — | — |
What changed
Revenue was $5K in Q2 2026, down 100% year over year and down 81% from the previous quarter.
Operating costs exceeded revenue by $8.4M, an operating margin of -167480.0%. Total costs fell 24% while revenue fell 100%. The quarter ended with a net loss of $7.7M, wider than the previous quarter's $7.2M loss.
Operating cash flow was −$6.5M. Non-cash charges added back $171K of depreciation and amortization and $552K of share-based compensation. Working capital and other items added $457K.
Questions
What was Bolt Biotherapeutics' revenue in the second quarter 2026?
Bolt Biotherapeutics (BOLT) reported revenue of $5K for the second quarter 2026 (Q2 2026), -100% from a year earlier and -81% from the quarter before.